Here is What you should know about Hoth Therapeutics, Inc. (HOTH) Stock
Hoth Therapeutics, Inc. (HOTH) a biotech Stock trading under $3 just went 46% high on massive volume. HOTH reported this morning that it has reached agreement with Tergus Pharma on the production of HT-001 based on GLP and GMP principles. The HT-001 topical formulation is designed to cure patients with mild to moderate skin disorders […]
Top 3 Blue-Chip Stocks to Watch For in 2021
Are you a sustainable, consistent stock? Here are the best blue-chip stocks to invest in next year. Blue-Chip stocks are investor favorites; these companies have high-quality business model and provide what an investor wants. Though there are investors which belong to different schools of thought. Get the hottest stocks to trade every day before the […]
What’s driving investors toward Bionano Genomics (BNGO), Is it worth a Buy?
There’s a recent push in Bionano stock after the Nasdaq compliance update and that’s what BNGO wants. Get the hottest stocks to trade every day before the market opens 100% free. Click here now. Bionano Genomics (BNGO) has been astonishing during this whole month. In December 2020, shares of the biosciences soared over 328%, which is […]
Palo Alto Networks Inc. [PANW] Stock Gets Reiterated At BTIG. It’s Still a Buy
BTIG maintained its Palo Alto Networks Inc. [NYSE:PANW] rating to the equivalent of Buy but changed the price target to $419 from $370, in a research note dated December 31, 2020. That figure represents around a 17.76% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with RBC Capital […]
CrowdStrike Holdings Inc. [CRWD] gets its Buy rating reiterated by BTIG
BTIG maintained its CrowdStrike Holdings Inc. [NASDAQ:CRWD] rating to the equivalent of Buy but changed the price target to $236 from $206, in a research note dated December 31, 2020. That figure represents around a 12.22% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with JP Morgan’s analysts […]
H.C. Wainwright reiterates Protalix BioTherapeutics Inc. [PLX] at Buy and assigns price target at $11
H.C. Wainwright maintained its Protalix BioTherapeutics Inc. [AMEX:PLX] rating to the equivalent of Buy but changed the price target to $11, in a research note dated December 31, 2020. That figure represents around a 212.5% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with H.C. Wainwright’s analysts reiterating […]
Morgan Stanley maintains Constellation Brands Inc. [STZ] at an Overweight rating with a $240 price target
Morgan Stanley maintained its Constellation Brands Inc. [NYSE:STZ] rating to the equivalent of Overweight but changed the price target to $240, in a research note dated December 31, 2020. That figure represents around a 9.98% premium from where the company’s shares closed on Wednesday. Some new analysts also started their coverage, with Wells Fargo’s analysts […]
Credit Suisse maintains Chart Industries Inc. [GTLS] at an Outperform rating with a $128 price target
Credit Suisse maintained its Chart Industries Inc. [NASDAQ:GTLS] rating to the equivalent of Outperform but changed the price target to $128 from $109, in a research note dated December 31, 2020. That figure represents around a 6.87% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with Cowen’s analysts […]
Helius Medical Technologies Inc (HSDT) Reveals Reverse Stock Split Before 2020 Last Bell
Helius Medical Technologies Inc. (HSDT) traded 2.50% higher on Wednesday. At $0.42 per share, the HSDT stock is down around 56.80% year to date. Currently, Helius Medical Technologies Inc. (HSDT) has a market cap of $20.54 million. The average volume for HSDT over the past month (560630 shares per day) is below its average volume […]
Credit Suisse reiterates Brown & Brown Inc. [BRO] rating to Neutral and sets new price target at $50
Credit Suisse maintained its Brown & Brown Inc. [NYSE:BRO] rating to the equivalent of Neutral but changed the price target to $50 from $47, in a research note dated December 31, 2020. That figure represents around a 8.10% premium from where the company’s shares closed on Wednesday. Other analysts also revised their coverage, with Morgan […]
